Awesome Neil
thanks for latest post and clarifications, myself and few others posters understood the Hemp yields of last year and not all was lost with harvest...
my curiosity has expanded from last BHC post...all with good conviction though....
is BHC agreements from April and May 2018 all going to Bio Health latest agreements or is it simply separate from Medcan arrangements and BHC...separate to manufacturing MM products, tablets, skin care and dried flowers.
As BHC have all the necessary licences and TGA approvals to manufactured the above products...
Bio health have TGA approvals to manufacture for Canntab, Pharmocann and Vitahemp products as Medcan have import export and manufacturing licences...with dried flowers, MM, TABS and skincare..
Yet as mention above, BHC have all the regulatory arrangements or are all three separate facilities under CGB umbrella with different licences and regulations within Australian states all in alignment to producing manufacturing under CGB industry...
just trying to figure out if all three facilities are all on the same game plan or separate from each other...
- Forums
- ASX - By Stock
- CGB
- Response from CGB
Response from CGB, page-7
-
- There are more pages in this discussion • 46 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add CGB (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
NRZ
NEURIZER LTD
Simon Kidston, Non--Executive Director
Simon Kidston
Non--Executive Director
Previous Video
Next Video
SPONSORED BY The Market Online